The global GLP-1 analogues market is experiencing unprecedented growth, driven by the increasing prevalence of type 2 diabetes and obesity, expanding therapeutic applications, and continuous innovation in drug formulations. According to industry estimates, the market was valued at US$ 51.6 billion in 2024 and is projected to reach US$ 211.8 billion by 2035, expanding at a robust CAGR of 13.7%...